Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma.

Nakchbandi W, Müller H, Singer MV, Lohr JM, Nakchbandi IA.

J Gastrointestin Liver Dis. 2008 Sep;17(3):285-90.

2.

Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma.

Nakchbandi W, Müller H, Singer MV, Löhr M, Nakchbandi IA.

Scand J Gastroenterol. 2006 Sep;41(9):1095-104.

PMID:
16938724
3.

Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.

Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ.

Am J Clin Oncol. 2009 Aug;32(4):348-52. doi: 10.1097/COC.0b013e31818c08ff.

PMID:
19363436
4.

Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.

Kornek GV, Pötter R, Selzer E, Schratter A, Ulrich-Pur H, Rogy M, Kraus G, Scheithauer W.

Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):665-71.

PMID:
11172947
5.
6.

Phase II study on combined intravenous and intra-arterial chemotherapy with gemcitabine and mitomycin C in patients with advanced pancreatic cancer.

Heinrich S, Kraft D, Staib-Sebler E, Schwarz W, Gog C, Vogl T, Lorenz M.

Hepatogastroenterology. 2013 Sep;60(126):1492-6. doi: 10.5754/hge11805.

PMID:
23933944
7.

Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study.

Kurosaki I, Kawachi Y, Nihei K, Tsuchiya Y, Aono T, Yokoyama N, Shimizu T, Hatakeyama K.

Pancreas. 2009 Mar;38(2):161-7. doi: 10.1097/MPA.0b013e31818815f7.

PMID:
18797423
8.

Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience.

Tuinmann G, Hegewisch-Becker S, Zschaber R, Kehr A, Schulz J, Hossfeld DK.

Anticancer Drugs. 2004 Jul;15(6):575-9.

PMID:
15205599
9.

Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.

Jacobs AD, Otero H, Picozzi VJ Jr, Aboulafia DM.

Cancer Invest. 2004;22(4):505-14.

PMID:
15565807
10.

Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.

Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P.

Cancer Invest. 2003;21(4):489-96.

PMID:
14533437
11.

Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.

Wilkowski R, Thoma M, Bruns C, Wagner A, Heinemann V.

JOP. 2006 Jul 10;7(4):349-60.

12.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD.

J Clin Oncol. 2005 May 20;23(15):3509-16.

PMID:
15908661
13.

Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, Nakagawa N, Sueda T.

J Surg Oncol. 2012 Aug 1;106(2):174-80. doi: 10.1002/jso.23068. Epub 2012 Feb 13.

PMID:
22331838
14.

Prospective randomized clinical trial of two drug delivery pathway in the treatment of inoperable advanced pancreatic carcinoma.

Han GH, Yin ZX, Meng XJ, He CY, Zhang HB, Sun AH, Wu KC, Ding J, Fan DM.

Chin J Dig Dis. 2006;7(1):45-8.

PMID:
16412037
15.

Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.

Li J, Merl M, Lee MX, Kaley K, Saif MW.

Expert Opin Drug Saf. 2010 Mar;9(2):207-13. doi: 10.1517/14740330903555181.

PMID:
20095915
16.

Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.

Lim KH, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1017-26. doi: 10.1007/s00280-011-1584-1. Epub 2011 Feb 17.

PMID:
21327930
17.

Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.

Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Aitini E, Marangolo M.

J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):51-7.

PMID:
16767907
18.

Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.

Lee J, Park JO, Kim WS, Lee SI, Song SY, Lim DH, Choi SH, Heo JS, Lee KT, Lee JK, Kim K, Jung CW, Im YH, Lee MH, Kang WK, Park K.

Oncology. 2004;66(1):32-7.

PMID:
15031596
19.

Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.

Uwagawa T, Misawa T, Tsutsui N, Ito R, Gocho T, Hirohara S, Sadaoka S, Yanaga K.

Am J Clin Oncol. 2013 Feb;36(1):44-8. doi: 10.1097/COC.0b013e31823a53b2.

PMID:
22157216
20.

Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.

Meyer F, Lueck A, Hribaschek A, Lippert H, Ridwelski K.

Chemotherapy. 2004 Dec;50(6):289-96. Epub 2004 Dec 8.

PMID:
15608445

Supplemental Content

Support Center